Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ATAI NASDAQ:CCCC NASDAQ:DAWN NASDAQ:DNTH On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATAIatai Life Sciences$3.74-3.6%$2.47$1.03▼$4.00$777.31M1.447.52 million shs7.36 million shsCCCCC4 Therapeutics$2.29-5.4%$1.65$1.09▼$7.36$171.84M2.941.97 million shs1.15 million shsDAWNDay One Biopharmaceuticals$7.21+3.9%$6.63$6.08▼$16.76$703.46M-1.271.37 million shs1.87 million shsDNTHDianthus Therapeutics$21.79-1.4%$18.72$13.36▼$32.27$710.74M1.38374,006 shs276,800 shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATAIatai Life Sciences+9.92%+43.70%+92.08%+153.59%+147.13%CCCCC4 Therapeutics+9.01%+19.80%+64.63%+50.31%-62.65%DAWNDay One Biopharmaceuticals+5.63%+4.83%+7.10%-12.15%-56.41%DNTHDianthus Therapeutics+6.56%+11.39%+28.49%+4.10%-21.02%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationATAIatai Life Sciences3.5675 of 5 stars3.84.00.00.03.91.70.6CCCCC4 Therapeutics2.4847 of 5 stars3.34.00.00.01.11.70.6DAWNDay One Biopharmaceuticals2.7848 of 5 stars3.63.00.00.02.52.50.0DNTHDianthus Therapeutics0.9526 of 5 stars3.60.00.00.00.00.80.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceATAIatai Life Sciences 3.50Strong Buy$9.00140.64% UpsideCCCCC4 Therapeutics 2.50Moderate Buy$12.00424.02% UpsideDAWNDay One Biopharmaceuticals 3.14Buy$29.00302.22% UpsideDNTHDianthus Therapeutics 3.13Buy$53.00143.23% UpsideCurrent Analyst Ratings BreakdownLatest CCCC, DNTH, DAWN, and ATAI Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/2/2025ATAIatai Life SciencesAegisSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy7/2/2025ATAIatai Life SciencesCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$11.00 ➝ $12.007/2/2025DNTHDianthus TherapeuticsWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform5/20/2025ATAIatai Life SciencesJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price Target$5.005/20/2025ATAIatai Life SciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.005/13/2025ATAIatai Life SciencesCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy5/13/2025DNTHDianthus TherapeuticsRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$58.00 ➝ $50.005/13/2025DNTHDianthus TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$40.00 ➝ $40.005/7/2025DAWNDay One BiopharmaceuticalsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$25.005/7/2025DAWNDay One BiopharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$30.00 ➝ $27.00(Data available from 7/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookATAIatai Life Sciences$310K2,417.01N/AN/A$0.69 per share5.42CCCCC4 Therapeutics$35.58M4.57N/AN/A$3.06 per share0.75DAWNDay One Biopharmaceuticals$131.16M5.57N/AN/A$4.99 per share1.44DNTHDianthus Therapeutics$6.24M112.30N/AN/A$11.91 per share1.83Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateATAIatai Life Sciences-$149.27M-$0.91N/AN/AN/AN/A-102.10%-77.55%8/12/2025 (Estimated)CCCCC4 Therapeutics-$105.32M-$1.47N/AN/AN/A-259.60%-45.86%-28.96%7/30/2025 (Estimated)DAWNDay One Biopharmaceuticals-$95.50M-$0.71N/AN/AN/A-42.66%-14.98%-13.04%8/5/2025 (Estimated)DNTHDianthus Therapeutics-$84.97M-$2.88N/AN/AN/A-1,544.23%-29.26%-27.87%8/6/2025 (Estimated)Latest CCCC, DNTH, DAWN, and ATAI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025DNTHDianthus Therapeutics-$0.86N/AN/AN/AN/AN/A8/12/2025Q2 2025ATAIatai Life Sciences-$0.13N/AN/AN/AN/AN/A8/7/2025Q2 2025CCCCC4 Therapeutics-$0.41N/AN/AN/A$5.24 millionN/A8/5/2025Q2 2025DAWNDay One Biopharmaceuticals-$0.35N/AN/AN/A$35.55 millionN/A5/14/2025Q1 2025ATAIatai Life Sciences-$0.19-$0.15+$0.04-$0.15N/A$1.56 million5/12/2025Q1 2025DNTHDianthus Therapeutics-$0.86-$0.82+$0.04-$0.82$0.81 million$1.16 million5/7/2025Q1 2025CCCCC4 Therapeutics-$0.48-$0.37+$0.11-$0.37$3.54 million$7.20 million5/6/2025Q1 2025DAWNDay One Biopharmaceuticals-$0.46-$0.35+$0.11-$0.35$30.28 million$30.76 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthATAIatai Life SciencesN/AN/AN/AN/AN/ACCCCC4 TherapeuticsN/AN/AN/AN/AN/ADAWNDay One BiopharmaceuticalsN/AN/AN/AN/AN/ADNTHDianthus TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioATAIatai Life Sciences0.084.074.07CCCCC4 TherapeuticsN/A5.705.70DAWNDay One BiopharmaceuticalsN/A10.6210.55DNTHDianthus TherapeuticsN/A15.9815.99Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipATAIatai Life Sciences28.41%CCCCC4 Therapeutics78.81%DAWNDay One Biopharmaceuticals87.95%DNTHDianthus Therapeutics47.53%Insider OwnershipCompanyInsider OwnershipATAIatai Life Sciences26.80%CCCCC4 Therapeutics8.73%DAWNDay One Biopharmaceuticals6.20%DNTHDianthus Therapeutics8.15%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableATAIatai Life Sciences80200.34 million146.65 millionOptionableCCCCC4 Therapeutics15071.01 million64.81 millionOptionableDAWNDay One Biopharmaceuticals60101.36 million95.08 millionOptionableDNTHDianthus Therapeutics8032.16 million29.54 millionOptionableCCCC, DNTH, DAWN, and ATAI HeadlinesRecent News About These CompaniesDianthus Therapeutics (NASDAQ:DNTH) Trading 5.9% Higher - Should You Buy?July 16, 2025 | marketbeat.comDianthus Therapeutics, Inc. (NASDAQ:DNTH) Receives Consensus Rating of "Buy" from BrokeragesJuly 15, 2025 | marketbeat.comDianthus Therapeutics Inc News (DNTH) - Investing.comJuly 11, 2025 | investing.comDianthus Therapeutics (NASDAQ:DNTH) Shares Down 4.9% - Here's WhyJuly 10, 2025 | marketbeat.comDianthus Therapeutics (NASDAQ:DNTH) Stock Price Up 8.4% - Time to Buy?July 9, 2025 | marketbeat.comWhat is William Blair's Forecast for DNTH FY2025 Earnings?July 4, 2025 | marketbeat.comMoody Aldrich Partners LLC Takes Position in Dianthus Therapeutics, Inc. (NASDAQ:DNTH)July 4, 2025 | marketbeat.comWilliam Blair Initiates Coverage of Dianthus Therapeutics (DNTH) with Outperform RecommendationJuly 3, 2025 | msn.comDianthus Therapeutics stock rises after William Blair initiates coverageJuly 2, 2025 | in.investing.comDianthus Therapeutics Shares Climb After Analyst Coverage BoostJuly 2, 2025 | msn.comDianthus Therapeutics (NASDAQ:DNTH) Shares Gap Up - Here's WhyJuly 2, 2025 | marketbeat.comDianthus Therapeutics (NASDAQ:DNTH) Earns Outperform Rating from Analysts at William BlairJuly 2, 2025 | marketbeat.comDNTH - Dianthus Therapeutics Inc Price vs Fair Value - MorningstarJune 26, 2025 | morningstar.comMDianthus Therapeutics (NASDAQ:DNTH) Stock Price Down 6% - What's Next?June 25, 2025 | marketbeat.comDNTH - Dianthus Therapeutics Inc Dividends - MorningstarJune 24, 2025 | morningstar.comMDNTH (NASDAQ:DNTH) Earnings Biotech Development Path Russell 1000June 23, 2025 | kalkinemedia.comKStifel Reaffirms Buy on Dianthus Therapeutics, Inc. (DNTH) with 186% UpsideJune 23, 2025 | finance.yahoo.comStifel Reaffirms Buy on Dianthus Therapeutics, Inc. (DNTH) with 186% UpsideJune 21, 2025 | insidermonkey.comDianthus Therapeutics to Webcast Presentation at the Jefferies Global Healthcare ConferenceMay 29, 2025 | globenewswire.comDianthus Therapeutics appoints new board memberMay 24, 2025 | investing.comDianthus Therapeutics Appoints Simon Read, Ph.D., to Board of DirectorsMay 22, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCCCC, DNTH, DAWN, and ATAI Company Descriptionsatai Life Sciences NASDAQ:ATAI$3.74 -0.14 (-3.61%) Closing price 04:00 PM EasternExtended Trading$3.76 +0.02 (+0.56%) As of 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Atai Life Sciences N.V., a clinical-stage biopharmaceutical company, develops and invests in various therapeutics to treat depression, anxiety, addiction, and other mental health disorders. Its product candidates include COMP360, a proprietary psilocybin which is in Phase 3 program; BPL-003, an intranasal formulation that is in Phase 2a and 2b clinical studies; TRD; VLS-01, an transmucosal film in Phase 1b clinical studies; and ELE-101, a serotonergic psychedelic that is in Phase 1/2a study, for the treatment of treatment resistant depression. The company also develop IBX-210, an intravenous formulation of ibogaine, and DMX-1002, an oral formulation of ibogaine indicated for the treatment of opioid use disorder; EMP-01, an oral formulation of an R-MDMA derivative being developed for the treatment of post-traumatic stress disorder; and EGX-A and EGX-B, psychedelic-like with novel, non-tryptamine structures with differentiated 5-HT receptor pharmacology. In addition, it offers RL-007, an orally bioavailable compound, which is a pro-cognitive neuromodulator for cognitive impairment associated with schizophrenia; and GRX-917, a deuterated etifoxine for the treatment of generalize anxiety disorder. Further, the company develops PCN-101, a subcutaneous formulation of R-ketamine, as a therapy for psychiatric indications initially focused on TRD; KUR-101, a formulation of deuterated mitragynine for the treatment of OUD; and RLS-01, indicated for treatment resistant depression. ATAI Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany with offices in New York and London.C4 Therapeutics NASDAQ:CCCC$2.29 -0.13 (-5.37%) Closing price 04:00 PM EasternExtended Trading$2.30 +0.01 (+0.61%) As of 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma, currently under Phase 1/2 clinical trials. The company is also developing CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies, currently under Phase 1/2 clinical trials; and CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC. It has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; Betta Pharmaceuticals, Co., Ltd.; and Merck Sharp & Dohme, LLC, as well as Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.Day One Biopharmaceuticals NASDAQ:DAWN$7.21 +0.27 (+3.89%) Closing price 04:00 PM EasternExtended Trading$7.34 +0.13 (+1.73%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.Dianthus Therapeutics NASDAQ:DNTH$21.79 -0.31 (-1.40%) Closing price 04:00 PM EasternExtended Trading$21.80 +0.01 (+0.05%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Krispy Kreme: A Meme Stock Sugar Rush or a Sustainable Treat? From Zero to Hero? Why GoPro's Rally Could Be More Than It Seems A Smokin’ Hot Entry Point for Chipotle Stock Opens in Q3 Alphabet’s Breakout Quarter Signals a New Leadership Phase Tesla Just Hit a Fork in the Road—Could the Bulls Lose Control? GE Vernova's Q2 Electrifies Stock, What's Next For This Top Name? Is Former Dividend Aristocrat AT&T a Buy After Q2 Earnings? What's Behind Opendoor Technologies' Rally? Is Meme Mania Back? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
